相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance
Zhanhong Xie et al.
CLINICAL LUNG CANCER (2021)
Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma
Qianyi Fan et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
Wenxing Gu et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
Keunchil Park et al.
CANCER (2021)
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR plus NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
Heather Burnett et al.
PLOS ONE (2021)
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J. Riely et al.
CANCER DISCOVERY (2021)
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
Francois Gonzalvez et al.
CANCER DISCOVERY (2021)
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial
Caicun Zhou et al.
JAMA ONCOLOGY (2021)
Lazertinib: First Approval
Sohita Dhillon
DRUGS (2021)
Role of several cytochrome P450s in the resistance and cross-resistance ; against imidacloprid and acetamiprid of Bemisia tabaci (Hemiptera: Aleyrodidae) MEAM1 cryptic species in Xinjiang, China
Cheng-song Zhou et al.
PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY (2020)
TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
G. R. Oxnard et al.
ANNALS OF ONCOLOGY (2020)
Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma
Yingwen Li et al.
BIOMACROMOLECULES (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Naoko Okura et al.
CLINICAL CANCER RESEARCH (2020)
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations
Riyaz Shah et al.
CLINICAL LUNG CANCER (2020)
Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Research and development of drug delivery systems based on drug transporter and nano-formulation
Yi Peng et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Yuxin Mu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.
Ki Hyeong Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance
Yiting Yang et al.
PHARMACEUTICS (2020)
Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance
Paramita Ray et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Andrew J. Piper-Vallillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
Jiao-jiao Yu et al.
NATURE COMMUNICATIONS (2020)
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)
Tongji Xie et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
Jiyun Lee et al.
CANCER RESEARCH AND TREATMENT (2019)
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics
Leonie Ferrer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Morana Vojnic et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
Hiroaki Tanaka et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
Ciric To et al.
CANCER DISCOVERY (2019)
Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
Zhanhong Xie et al.
CANCER BIOLOGY & THERAPY (2019)
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Qiming Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
Takeshi Jimbo et al.
Oncotarget (2019)
1177PDClinical study of personalized neoantigen peptide vaccination in advanced NSCLC patients
X Du et al.
ANNALS OF ONCOLOGY (2019)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Shunli Peng et al.
MOLECULAR CANCER (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
After decades, progress against an 'undruggable' cancer target
Jocelyn Kaiser
SCIENCE (2019)
Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
Lai Wei et al.
NATURE COMMUNICATIONS (2019)
Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations
Shanhe Wan et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2019)
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Kei Namba et al.
MOLECULAR CANCER RESEARCH (2019)
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Myung-Ju Ahn et al.
LANCET ONCOLOGY (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance
Yuxiang Ma et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
EGFR-TKIs resistance via EGFR-independent signaling pathways
Qian Liu et al.
MOLECULAR CANCER (2018)
Third generation EGFR TKIs: current data and future directions
Chee-Seng Tan et al.
MOLECULAR CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Tobias Grabe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Jana Fassunke et al.
NATURE COMMUNICATIONS (2018)
Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation
Jessie Peh et al.
CELL CHEMICAL BIOLOGY (2018)
Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC
L. Byers et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Myung-Ju Ahn et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial
Baohui Han et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R±T790M) NSCLC
Hatim Husain et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Jody C. Chuang et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2017)
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2017)
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Y. K. Shi et al.
ANNALS OF ONCOLOGY (2017)
Risk factors of Lung Cancer in nonsmoker
Nahid Akhtar et al.
CURRENT PROBLEMS IN CANCER (2017)
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade
Zhaolin Chen et al.
CANCER LETTERS (2016)
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
Yong Jia et al.
CANCER RESEARCH (2016)
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
Shiyong Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC
D. L. Gibbons et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature
Shi-Yu Jiang et al.
MEDICINE (2016)
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Paul E. Hughes et al.
MOLECULAR CANCER THERAPEUTICS (2016)
AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Xiao Xu et al.
MOLECULAR CANCER THERAPEUTICS (2016)
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
D-W Wu et al.
CELL DEATH & DISEASE (2016)
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
E-E Ke et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Matthew G. Oser et al.
LANCET ONCOLOGY (2015)
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Masayuki Takeda et al.
LUNG CANCER (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
L. V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
Erin M. Tricker et al.
CANCER DISCOVERY (2015)
cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
Nele Van Der Steen et al.
CANCERS (2015)
Butein, a Novel Dual Inhibitor of MET and EGFR, Overcomes Gefitinib-Resistant Lung Cancer Growth
Sung Keun Jung et al.
MOLECULAR CARCINOGENESIS (2015)
MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
Jin Kyung Rho et al.
CANCER RESEARCH (2014)
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
Lorenza Landi et al.
CLINICAL LUNG CANCER (2014)
Icotinib: activity and clinical application in Chinese patients with lung cancer
Yong-Song Guan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
M. Raymond V. Finlay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Peter M. Ellis et al.
LANCET ONCOLOGY (2014)
The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer
Yanming Deng et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Afatinib: First Global Approval
Rosselle T. Dungo et al.
DRUGS (2013)
HER2 and lung cancer
Lorenza Landi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi et al.
LANCET ONCOLOGY (2013)
Personalizing Therapy in Advanced Non-Small Cell Lung Cancer
Liza C. Villaruz et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Targeting the EGFR signaling pathway in cancer therapy
Parthasarathy Seshacharyulu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells
Tian Li et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2012)
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller et al.
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
Yun-Ju Chen et al.
PLOS ONE (2011)
Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Martin H. Cohen et al.
ONCOLOGIST (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
PIK3CA mutations and copy number gains in human lung cancers
Hiromasa Yamamoto et al.
CANCER RESEARCH (2008)
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases
Giuseppe Altavilla et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
Alison Reid et al.
EUROPEAN JOURNAL OF CANCER (2007)
Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations
Bing Liu et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Shizhen Emily Wang et al.
CANCER CELL (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
FDA drug approval summary:: Erlotinib (Tarceva®) tablets
MH Cohen et al.
ONCOLOGIST (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Epidermal growth factor receptor: mechanisms of activation and signalling
RN Jorissen et al.
EXPERIMENTAL CELL RESEARCH (2003)
FDA drug approval summary: Gefitinib (ZD1839) (Iressa (R)) tablets
MH Cohen et al.
ONCOLOGIST (2003)
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
